Stoke Therapeutics Inc STOK:NASDAQ

Last Price$14.89NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change+1.17(8.53%)
Bid (Size)$10.17 (1)
Ask (Size)$27.00 (4)
Day Low / High$13.77 - 15.48
Volume375.0 K
  • Latest Stories
  • Commentary and Analysis
--Credit Suisse Lowers Stoke Therapeutics' Price Target to $54 from $58, Keeps Outperform Rating
10:41AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Stoke Therapeutics to $33 From $32, Maintains Outperform Rating
2:51PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

BofA Securities Adjusts Stoke Therapeutics' Price Target to $40 from $43, Keeps Buy Rating
11:12AM ET 3/16/2022 MT Newswires

Stoke Therapeutics (STOK) has an average rating of buy and price targets ranging from $32 to $83, according to analysts polled by Capital IQ. (MT Newswires...

--Wedbush Adjusts Stoke Therapeutics' Price Target to $32 From $48; Outperform Rating Kept
10:09AM ET 3/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Stoke Therapeutics Q4 Net Loss Widens
7:28AM ET 3/10/2022 MT Newswires

Stoke Therapeutics (STOK) reported a Q4 net loss Thursday of $0.66 per diluted share, widening from a $0.42 loss a year earlier. Analysts polled by...

Jefferies & Co Initiates Coverage on Stoke Therapeutics With Buy Rating, $50 Price Target
10:29AM ET 1/31/2022 MT Newswires

Stoke Therapeutics (STOK) has an average rating of Buy and price targets ranging from $41 to $83, according to analysts polled by Capital IQ. (MT Newswires...

Acadia, Stoke to Develop RNA-Based Treatments for Genetic Neurological Disorders
10:52AM ET 1/10/2022 MT Newswires

Acadia Pharmaceuticals (ACAD) and Stoke Pharmaceuticals (STOK) said Monday they have formed a partnership to discover, develop and commercialize novel...

Stoke Therapeutics Shares Interim Data on STK-001 to Treat Dravet Syndrome
1:55PM ET 12/03/2021 MT Newswires

Stoke Therapeutics (STOK) said Friday that a phase 1/2a study of its STK-001 candidate to treat Dravet syndrome showed that 70.6% of patients saw a...

BofA Securities Starts Stoke Therapeutics at Buy With $43 Price Target
6:35AM ET 12/03/2021 MT Newswires

Stoke Therapeutics (STOK) has an average rating of outperform and price targets ranging from $34 to $83, according to analysts polled by Capital IQ. (MT...

Stoke Therapeutics Shares Rise Following JPMorgan Upgrade
1:54PM ET 11/22/2021 MT Newswires

Stoke Therapeutics (STOK) was up nearly 14% after JPMorgan upgraded the company to overweight from neutral. The investment firm's price target on the...